Several case series have reported the use of intravitreal anti-VEGF, as bevacizumab and conbercept, as a primary or secondary treatment for exudative CCH.5–8 A study of cytokine levels in aqueous humor samples from patients with CCH has shown increased levels of VEGF.9 Given the low risk profile of these injections, the use of intravitreal injections of bevacizumab has been proposed as an alternative to PDT given the unavailability of Visudyne. Here, VEGFA is linked to columnar cell hyperplasia of the breast.